bioRxivMicrobiologyPreprint
The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics
T. Gil-Gil, B. A. Berryhill, J. A. Manuel, A. P. Smith, F. Baquero, B. R. Levin
Abstract
Traditionally, bacteriostatic antibiotics are agents able to arrest bacterial growth. Despite being traditionally viewed as unable to kill bacterial cells, when they are used clinically the outcome of these drugs is frequently as effective as when a bactericidal drug is used. We explore the dynamics of Escherichia coli after exposure to two ribosome-targeting bacteriostatic antibiotics, chloramphenicol and azithromycin, for thirty days. The results of our experiments provide evidence that bacteria exposed to these drugs replicate, evolve, and generate a sub-population of small colony variants (SCVs) which are resistant to multiple drugs. These SCVs contribute to the evolution of heteroresistance and rapidly revert to a susceptible state once the antibiotic is removed. Stated another way, exposure to bacteriostatic drugs selects for the evolution of heteroresistance in populations previously lacking this trait. More generally, our results question the definition of bacteriostasis as populations exposed to bacteriostatic drugs are replicating despite the lack of net growth.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Antibiotic killing of drug-induced bacteriostatic cells
Teresa Gil‐Gil, Brandon A. Berryhill·Antimicrobial Agents and ChemotherapyPeer-reviewed·Mar 26, 2025
- Antibiotic resistant bacteria survive treatment by doubling while shrinking
Adrian Campey, Urszula Łapińska, … Stefano Pagliara·mBioPeer-reviewed·Nov 20, 2024
- Single-cell phenotypic characteristics of phenotypic resistance under recurring antibiotic exposure in Escherichia coli
S. Kollerova, L. Jouvet, … U. K. Steiner·bioRxiv·May 26, 2021
- Drug mode of action and resource constraints modulate antimicrobial resistance evolution
O. Delaney, A. D. Letten, J. Engelstädter·bioRxiv·Aug 29, 2023
- Cryptic Evolution of Heteroresistance as Adaptation to Treatment Interruptions
Muqing Ma, Minchae Kang, … Minsu Kim·bioRxiv·May 18, 2026
- Dynamic growth trajectories distinguish bacteriostatic and bactericidal antibiotics at subinhibitory concentrations
Elizabeth Vaisbourd, David S. Glass, … Uri S. Alon·bioRxiv·Jun 14, 2025